Dysport contains the substance called botulinum toxin type A as its active ingredient. Inactive ingredients of Dysport include human albumin, lactose and protein from cow?s milk.
Dysport was originally developed for the treatment of neurological and ophthalmic conditions in the early 1990s in the United Kingdom and has established clinical success. Patients with excessive sweating under the armpits (axillary hyperhidrosis) are also treated with this product.
Dysport is manufactured by Ipsen Biopharm Ltd., a British company with headquarters in Wrexham, UK. Dysport is exclusively distributed by Tercica, Inc., a subsidiary company of Ipsen Group with headquarters at Brisbane, CA and Medicis Aesthetics Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation with headquarters at Scottsdale, AZ.
Dysport contains substance called botulinum toxin type A that relaxes the muscle. Botulinum toxin is derived from Clostridium botulinum bacteria that intercept the discharge of acetylcholine from the nerve endings that causes the contraction of muscles.
For the improvement of the appearance of glabellar lines, Dysport temporarily impede the tightening of muscles found between the eyebrows for about 4 months.
For the treatment of abnormal head position and neck pain caused by cervical dystonia (CD), Dysport lessens the muscle spasm that causes the CD by softening the muscle for about 12 to 16 weeks. Neck pain and abnormal head position as symptoms to CD is thereby reduced.
Dysport works in two functions, which is by inhibiting the release of acetylcholine and at the same time blocks the neuromuscular activity.
Dysport is indicated for the treatment of the following conditions specifically indicated in the medication guide:
Abnormal head position (spasmodic torticolitis) and neck pain brought about by the condition called cervical dystonia (CD) in adults,
Temporary improve the appearance of moderate to severe frown lines found between the eyebrows (glabellar lines) in patients younger than 65 years old.